KR101309409B1 - Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체 - Google Patents

Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체 Download PDF

Info

Publication number
KR101309409B1
KR101309409B1 KR1020077009820A KR20077009820A KR101309409B1 KR 101309409 B1 KR101309409 B1 KR 101309409B1 KR 1020077009820 A KR1020077009820 A KR 1020077009820A KR 20077009820 A KR20077009820 A KR 20077009820A KR 101309409 B1 KR101309409 B1 KR 101309409B1
Authority
KR
South Korea
Prior art keywords
alkyl
cyclosporine
compound
straight
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077009820A
Other languages
English (en)
Korean (ko)
Other versions
KR20070073841A (ko
Inventor
한스 게오르그 플리리
데이비드 렌위크 호우크
Original Assignee
싸이넥시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이넥시스, 인크. filed Critical 싸이넥시스, 인크.
Publication of KR20070073841A publication Critical patent/KR20070073841A/ko
Application granted granted Critical
Publication of KR101309409B1 publication Critical patent/KR101309409B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020077009820A 2004-10-01 2005-09-30 Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체 Expired - Fee Related KR101309409B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61515204P 2004-10-01 2004-10-01
US60/615,152 2004-10-01
US70762605P 2005-08-11 2005-08-11
US60/707,626 2005-08-11
PCT/US2005/035533 WO2006039668A2 (en) 2004-10-01 2005-09-30 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection

Publications (2)

Publication Number Publication Date
KR20070073841A KR20070073841A (ko) 2007-07-10
KR101309409B1 true KR101309409B1 (ko) 2013-09-23

Family

ID=36143148

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077009820A Expired - Fee Related KR101309409B1 (ko) 2004-10-01 2005-09-30 Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체

Country Status (19)

Country Link
US (2) US20100167996A1 (enExample)
EP (1) EP1802650B1 (enExample)
JP (2) JP5139065B2 (enExample)
KR (1) KR101309409B1 (enExample)
CN (1) CN101773661B (enExample)
AT (1) ATE530561T1 (enExample)
AU (1) AU2005292162B2 (enExample)
BR (1) BRPI0516737A (enExample)
CA (1) CA2583494C (enExample)
DK (1) DK1802650T3 (enExample)
ES (1) ES2373450T3 (enExample)
IL (1) IL182315A (enExample)
MX (1) MX2007003538A (enExample)
NZ (1) NZ554514A (enExample)
PL (1) PL1802650T3 (enExample)
PT (1) PT1802650E (enExample)
RU (1) RU2399628C2 (enExample)
SI (1) SI1802650T1 (enExample)
WO (1) WO2006039668A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7696167B2 (en) 2004-11-22 2010-04-13 Astellas Pharma Inc. Cyclic peptide compound
BRPI0616476A2 (pt) * 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
CA2623898C (en) 2005-10-26 2013-12-24 Astellas Pharma Inc. New cyclic peptide compounds
CA2643680A1 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors and their uses
ATE502633T1 (de) * 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
EP2027761A1 (fr) * 2006-06-02 2009-02-25 Claude Annie Perrichon Gestion des electrons actifs
BRPI0719189A2 (pt) * 2006-10-12 2018-08-14 Univ Kyushu Nat Univ Corp uso de ciclosporinas modificadas
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
US20080255038A1 (en) * 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
ES2396170T3 (es) 2007-05-02 2013-02-19 Astellas Pharma Inc. Nuevos compuestos péptídicos ciclicos
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
BRPI0911709A2 (pt) 2008-07-30 2017-06-20 Isotechnika Labs Inc composto, processo para a produção de um composto, composição farmacêutica e método de tratar uma doença mediada a ciclofilina em um mamífero
EP2376524B1 (en) * 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
WO2010080874A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
SG173180A1 (en) 2009-01-30 2011-09-29 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
US20110144005A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
BR112012014729A2 (pt) * 2009-12-18 2016-03-29 Boehringer Ingelheim Int terapia combinada contra hcv
AU2010339460A1 (en) 2009-12-30 2012-07-19 Scynexis Inc. Cyclosporine analogues
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2012009715A2 (en) 2010-07-16 2012-01-19 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012021796A2 (en) 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
EP2624826B1 (en) 2010-10-08 2018-07-18 Novartis AG Vitamin e formulations of sulfamide ns3 inhibitors
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JP6093307B2 (ja) * 2010-12-03 2017-03-08 エス アンド ティー グローバル インク． ウイルス感染の治療および予防のための新規シクロスポリン誘導体
JP6144627B2 (ja) 2010-12-15 2017-06-07 コントラヴィア ファーマシューティカルズ、インク． アミノ酸１および３で修飾されたシクロスポリン類似体分子
RU2448690C1 (ru) * 2011-03-15 2012-04-27 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма пролонгированного действия нестероидного противовоспалительного средства кетопрофен, способ получения
WO2013028615A2 (en) * 2011-08-19 2013-02-28 S&T Golbal Inc. Novel cyclosporin derivatives for the treatment and prevention of viral infections
EP2855508B1 (en) 2012-06-01 2018-02-14 Allergan, Inc. Cyclosporin a analogs
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
SG11201601274QA (en) * 2013-08-26 2016-03-30 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
US10077289B2 (en) 2015-03-31 2018-09-18 Allergan, Inc. Cyclosporins modified on the MeBmt sidechain by heterocyclic rings
WO2017004304A1 (en) * 2015-06-30 2017-01-05 Cypralis Limited Novel macrocycles
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
AU2020363688A1 (en) 2019-10-12 2022-04-21 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of nephrotoxin-induced kidney injuries
IL296586B1 (en) * 2020-03-26 2026-04-01 Farsight Medical Tech Shanghai Co Ltd Cyclophilin inhibitors and their uses
CN113694177B (zh) * 2020-04-15 2022-06-17 睿诺医疗科技（上海）有限公司 器官损伤的预防和治疗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994299A (en) * 1996-12-24 1999-11-30 Rhone-Poulenc Rorer, S.A. Cyclosporin compounds, their preparation and the pharmaceutical compositions which contain them
KR20010052766A (ko) * 1998-06-12 2001-06-25 침머만 다니엘 신규한 사이클로스포린

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) * 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) * 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
ATE148469T1 (de) * 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
US5863550A (en) * 1993-03-31 1999-01-26 Tokyo Tanabe Company Limited Cholestasis ameliorant
CA2167537A1 (en) * 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
US5739105A (en) * 1994-06-01 1998-04-14 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
PL324531A1 (en) * 1995-07-17 1998-06-08 Chem Ag C Derivatives of cyclosporin effective against hiv virus
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2780061B1 (fr) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
PT1091975E (pt) * 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6521595B1 (en) * 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) * 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
BRPI0616476A2 (pt) * 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
US8329658B2 (en) * 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
ATE502633T1 (de) * 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
US7576057B2 (en) * 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
US20080255038A1 (en) * 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US9090671B2 (en) * 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
EP2376524B1 (en) * 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
WO2010080874A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
WO2010080878A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Combination of a cyclosporine derivative and nucleosides for treating hcv
US20110144005A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994299A (en) * 1996-12-24 1999-11-30 Rhone-Poulenc Rorer, S.A. Cyclosporin compounds, their preparation and the pharmaceutical compositions which contain them
KR20010052766A (ko) * 1998-06-12 2001-06-25 침머만 다니엘 신규한 사이클로스포린

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Hepatology. Vol. 38, No. 5, pp. 1282-1288(2003) *
Hepatology. Vol. 38, No. 5, pp. 1282-1288(2003)*

Also Published As

Publication number Publication date
IL182315A0 (en) 2007-07-24
US20100167996A1 (en) 2010-07-01
PT1802650E (pt) 2011-12-30
MX2007003538A (es) 2008-01-16
AU2005292162B2 (en) 2011-11-10
RU2399628C2 (ru) 2010-09-20
ES2373450T3 (es) 2012-02-03
EP1802650A2 (en) 2007-07-04
EP1802650A4 (en) 2008-08-20
KR20070073841A (ko) 2007-07-10
SI1802650T1 (sl) 2012-03-30
WO2006039668A2 (en) 2006-04-13
JP2008514732A (ja) 2008-05-08
CN101773661B (zh) 2013-09-25
WO2006039668A3 (en) 2007-04-19
US20120264679A1 (en) 2012-10-18
BRPI0516737A (pt) 2008-04-29
DK1802650T3 (da) 2012-02-06
PL1802650T3 (pl) 2012-04-30
WO2006039668B1 (en) 2007-05-31
ATE530561T1 (de) 2011-11-15
JP2012167113A (ja) 2012-09-06
CN101773661A (zh) 2010-07-14
CA2583494A1 (en) 2006-04-13
HK1108703A1 (en) 2008-05-16
JP5139065B2 (ja) 2013-02-06
EP1802650B1 (en) 2011-10-26
IL182315A (en) 2013-08-29
CA2583494C (en) 2014-01-21
NZ554514A (en) 2010-10-29
AU2005292162A1 (en) 2006-04-13
RU2007116119A (ru) 2008-11-10

Similar Documents

Publication Publication Date Title
KR20070073841A (ko) Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체
US7718767B2 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
JP5322647B2 (ja) ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
JP5820722B2 (ja) シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
JP5517454B2 (ja) Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
US20120010131A1 (en) Novel cyclosporin analogues
CN101068829B (zh) 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
HK1108703B (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160911

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160911

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000